
Gossamer Bio, Inc.: updates and filings
Price
$11.23
November 19, 2026Market cap $69M
What Ploutos Investor adds for Gossamer Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
- 28MonOtherOther material eventsDocument
- 23WedOtherOther material eventsDocument
- 16WedPeopleOfficer or director changeDocument
- 11FriShareholdersChange to shareholders' rights, amended articles or bylaws, other material eventsDocument
- 9WedOtherOther material eventsDocument
- 3ThuShareholdersAmended articles or bylawsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Shelf registration for future offeringsFormS-3
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Results of operationsForm8-K
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 29, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 28, 2026Shareholder voteForm8-K
- Oct 8, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 28, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 28, 2026Other material eventsForm8-K
- Sep 23, 2026Other material eventsForm8-K
- Sep 16, 2026Annual meeting proxy statementFormDEF 14A
- Sep 16, 2026Officer or director changeForm8-K
- Sep 11, 2026Change to shareholders' rights, amended articles or bylaws, other material eventsForm8-K
- Sep 9, 2026Other material eventsForm8-K
- Sep 4, 2026FilingFormD
- Sep 3, 2026Preliminary proxy statementFormPRE 14A
- Sep 3, 2026Amended articles or bylawsForm8-K
- Aug 26, 2026Amended articles or bylawsForm8-K
- Aug 24, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 21, 2026Material agreement entered, unregistered sale of shares, amended articles or bylaws, Regulation FD disclosureForm8-K
- Aug 13, 2026Results of operationsForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 29, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 28, 2026 | 8-K | Shareholder vote | Document |
| Oct 8, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 28, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 28, 2026 | 8-K | Other material events | Document |
| Sep 23, 2026 | 8-K | Other material events | Document |
| Sep 16, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Sep 16, 2026 | 8-K | Officer or director change | Document |
| Sep 11, 2026 | 8-K | Change to shareholders' rights, amended articles or bylaws, other material events | Document |
| Sep 9, 2026 | 8-K | Other material events | Document |
| Sep 4, 2026 | D | Filing | Document |
| Sep 3, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Sep 3, 2026 | 8-K | Amended articles or bylaws | Document |
| Aug 26, 2026 | 8-K | Amended articles or bylaws | Document |
| Aug 24, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 21, 2026 | 8-K | Material agreement entered, unregistered sale of shares, amended articles or bylaws, Regulation FD disclosure | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 19, 2018.
The full analysis
What do Gossamer Bio's filings show?
The filings are where every one of Gossamer Bio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.